Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00746954 · ClinicalTrials.gov registry record · Phase 3
Buspirone as a Potential Treatment for Recurrent Central Apnea
A Phase 3 study, sponsored by VA Office of Research and Development.
- Terminated
- Registry status
- Phase 3
- Development phase
- 8
- Enrollment target
NCT00746954: Clinical Trial Phase 3 study, sponsored by VA Office of Research and Development.
NCT00746954 is a Phase 3 study that was terminated before completion, run by VA Office of Research and Development. The registered enrollment target is 8 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00746954, a Phase 3 study, was terminated before completion, sponsored by VA Office of Research and Development.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether buspirone compared to acetazolamide and to placebo will reduce the number and/or severity of breathing pauses during sleep that occur in some patients with Heart Failure.
Interventions
- DRUG Acetazolamide
- DRUG Buspirone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2008-09 |
| Est. Completion | 2011-12 |
| Phase | Phase 3 |
Why NCT00746954 stopped before completion
NCT00746954 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Acetazolamide is the first listed.
NCT00746954 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00746954 about?
NCT00746954 is a clinical study titled "Buspirone as a Potential Treatment for Recurrent Central Apnea". The purpose of this study is to determine whether buspirone compared to acetazolamide and to placebo will reduce the number and/or severity of breathing pauses during sleep that occur in some patients with Heart Failure.
What is the current status of trial NCT00746954?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 8 participants. The study started on 2008-09. Estimated completion is 2011-12.
What interventions are being tested in trial NCT00746954?
The interventions under investigation include: Acetazolamide (DRUG), Buspirone (DRUG).
Who is sponsoring clinical trial NCT00746954?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00746954's enrollment target sits among peer trials
8 1993rd of 2000 higher than 6 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia